The Journal of Immunology, Vol 153, Issue 8 3408-3416, Copyright © 1994 by American Association of Immunologists

ARTICLES

Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors

DM Essayan, SK Huang, BJ Undem, A Kagey-Sobotka and LM Lichtenstein
Division of Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224.

Cyclic nucleotide phosphodiesterase (PDE) enzymes are felt to play a role in the regulation of inflammatory responses through their effects on cAMP. In this study, we investigated the effects of nonselective and isozyme selective PDE inhibitors on the proliferative responses of peripheral blood mononuclear cells (PBMCs) to ragweed (RW, a Th2 stimulus), tetanus toxoid (TT, a Th1 stimulus), and phytohemagglutinin in ragweed-allergic patients. The nonselective PDE inhibitor 3-isobutyl- 1-methylxanthine (IBMX) produced nearly identical concentration- dependent inhibition for PBMCs cultured with either Ag (RW and TT) or mitogen (phytohemagglutinin). Neither the type V inhibitor, zaprinast, nor the type III inhibitor, siguazodan, was effective at inhibiting antigen- or mitogen-driven proliferative responses of human PBMCs. The type IV inhibitor, rolipram, was unique in its ability to inhibit the RW-driven proliferative response and, to a lesser extent, the TT-driven proliferative response. However, rolipram was ineffective at inhibiting the mitogen-driven proliferative response. Only with a combination of type III and type IV inhibitors could the efficacy on the TT response be made to approximate that of the type IV inhibitor alone in the RW- driven system. Although the efficacies of IBMX and rolipram were identical in the RW-driven system, the IC50 value of the latter was 10- fold lower, similar to the difference noted in the TT-driven system between IBMX alone and the combination of rolipram with siguazodan. Dose-response curves generated by using the D- or L-isomers of rolipram were not appreciably different from each other or from the curve generated with racemic rolipram. The addition of supraphysiologic doses of human rIL-2 and rIL-4 was unable to counteract the inhibitory effect of IBMX or rolipram. These data support the hypothesis that modulation of proliferation of PBMCs by selective PDE inhibitors varies in sensitivity with the type of stimulus used, and that the type IV PDE exerts the predominant cAMP-associated regulatory effect on allergen- driven proliferation. Finally, the inhibitory effect induced by rolipram is independent of its stereochemistry and cannot be exclusively attributed to deficits in IL-2 or IL-4.

This article has been cited by other articles:

				P. E. Losco, E. W. Evans, S. A. Barat, P. E. Blackshear, L. Reyderman, J. S. Fine, L. A. Bober, J. C. Anthes, E. J. Mirro, and F. M. Cuss The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys Toxicol Pathol, April 1, 2004; 32(3): 295 - 308. [Abstract] [PDF]

				G. Yang, K. W. McIntyre, R. M. Townsend, H. H. Shen, W. J. Pitts, J. H. Dodd, S. G. Nadler, M. McKinnon, and A. J. Watson Phosphodiesterase 7A-Deficient Mice Have Functional T Cells J. Immunol., December 15, 2003; 171(12): 6414 - 6420. [Abstract] [Full Text] [PDF]

				J. L. Jimenez, C. Punzon, J. Navarro, M. A. Munoz-Fernandez, and M. Fresno Phosphodiesterase 4 Inhibitors Prevent Cytokine Secretion by T Lymphocytes by Inhibiting Nuclear Factor-kappa B and Nuclear Factor of Activated T Cells Activation J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 753 - 759. [Abstract] [Full Text] [PDF]

				C. Méhats, G. Tanguy, B. Paris, B. Robert, N. Pernin, F. Ferré, and M.-J. Leroy Pregnancy Induces a Modulation of the cAMP Phosphodiesterase 4-Conformers Ratio in Human Myometrium: Consequences for the Utero-Relaxant Effect of PDE4-Selective Inhibitors J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 817 - 823. [Abstract] [Full Text]

				G. Hartmann, C. Bidlingmaier, B. Siegmund, S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H. A. Lehr, and S. Endres Specific Type IV Phosphodiesterase Inhibitor Rolipram Mitigates Experimental Colitis in Mice J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 22 - 30. [Abstract] [Full Text]

				J. Navarro, C. Punzon, J. L. Jimenez, E. Fernandez-Cruz, A. Pizarro, M. Fresno, and M. A. Munoz-Fernandez Inhibition of Phosphodiesterase Type IV Suppresses Human Immunodeficiency Virus Type 1 Replication and Cytokine Production in Primary T Cells: Involvement of NF-kappa B and NFAT J. Virol., June 1, 1998; 72(6): 4712 - 4720. [Abstract] [Full Text] [PDF]

				M. S. Barnette, S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 420 - 426. [Abstract] [Full Text]

				G. G. Bashian, C. M. Braun, S.-K. Huang, A. Kagey-Sobotka, L. M. Lichtenstein, and D. M. Essayan Differential Regulation of Human, Antigen-specific Th1 and Th2 Responses by the B-7 Homologues, CD80 and CD86 Am. J. Respir. Cell Mol. Biol., August 1, 1997; 17(2): 235 - 242. [Abstract] [Full Text]

				D. M. Essayan, A. Kagey-Sobotka, L. M. Lichtenstein, and S.-K. Huang Differential Regulation of Human Antigen-Specific Th1 and Th2 Lymphocyte Responses by Isozyme Selective Cyclic Nucleotide Phosphodiesterase Inhibitors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 505 - 512. [Abstract] [Full Text]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]

				F. Gantner, S. Küsters, A. Wendel, A. Hatzelmann, C. Schudt, and G. Tiegs Protection from T Cell-Mediated Murine Liver Failure by Phosphodiesterase Inhibitors J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 53 - 60. [Abstract] [Full Text]

				M. Grange, C. Sette, M. Cuomo, M. Conti, M. Lagarde, A.-F. Prigent, and G. Nemoz The cAMP-specific Phosphodiesterase PDE4D3 Is Regulated by Phosphatidic Acid Binding. CONSEQUENCES FOR cAMP SIGNALING PATHWAY AND CHARACTERIZATION OF A PHOSPHATIDIC ACID BINDING SITE J. Biol. Chem., October 20, 2000; 275(43): 33379 - 33387. [Abstract] [Full Text] [PDF]